Financials in USD. Standardized financial statements.
A compact view of how Arcturus Therapeutics Holdings Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $67.22M | $138.39M | $157.75M | $205.75M | $12.36M | $9.54M | $20.79M | $15.75M | $13.00M | $20.38M |
| Revenue Growth? | -51.4% | -12.3% | -23.3% | +1564.8% | +29.6% | -54.1% | +32.0% | +21.2% | -36.2% | 0.0% |
| Cost of Revenue? | $3.02M | $0 | $0 | $0 | $0 | $55.95M | $0 | $16.98M | $410,000 | $294,000 |
| Gross Profit? | $64.20M | $138.39M | $157.75M | $205.75M | $12.36M | -$46.41M | $20.79M | -$1.23M | $12.59M | $20.09M |
| Gross Margin? | +95.5% | +100.0% | +100.0% | +100.0% | +100.0% | -486.5% | +100.0% | -7.8% | +96.8% | +98.6% |
| Operating Expenses? | $139.15M | $234.06M | $235.95M | $193.58M | $215.21M | $25.12M | $46.30M | $37.56M | $23.49M | $25.17M |
| Operating Income? | -$74.95M | -$95.67M | -$78.20M | $12.18M | -$202.85M | -$71.52M | -$25.51M | -$21.81M | -$10.49M | -$25.17M |
| EBITDA? | -$71.93M | -$77.40M | -$24.16M | $13.70M | -$201.66M | -$70.64M | -$24.45M | -$20.71M | -$10.34M | -$947,000 |
| Income Before Tax | -$65.78M | -$80.94M | -$27.89M | $10.64M | -$203.67M | -$72.15M | -$25.99M | -$21.79M | -$10.90M | -$24.53M |
| Income Tax Expense | $0 | -$4,000 | $1.83M | $1.29M | $0 | $0 | $0 | $212,000 | $1,000 | $73,000 |
| Net Income? | -$65.78M | -$80.94M | -$29.73M | $9.35M | -$203.67M | -$72.15M | -$25.99M | -$21.79M | -$10.90M | -$24.60M |
| EPS? | $-2.40 | $-3.00 | $-1.12 | $0.35 | $-7.74 | $-3.55 | $-2.13 | $-2.16 | $-3.53 | $-6.25 |
| Diluted EPS? | $-2.40 | $-3.00 | $-1.12 | $0.35 | $-7.74 | $-3.55 | $-2.13 | $-2.16 | $-3.53 | $-6.25 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality